PSMA binding ligand-linker conjugates and methods for using
First Claim
Patent Images
1. A compound of the formula:
- B-L-Dor a salt thereof, wherein B is a prostate specific membrane antigen (PSMA) binding ligand;
L comprises at least one polyoxyalkylene portion and at least one Glu, Asp, Cys, beta-amino Ala, Gly, beta Ala, amino valeric acid, or amino caproic acid, wherein the linker is at least 14 atoms in length and has at least one side chain group comprising a hydrophobic alkyl, cycloalkyl, aryl or arylalkyl; and
D is a radioactive isotope of a metal coordinated to a chelating group.
1 Assignment
0 Petitions
Accused Products
Abstract
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
272 Citations
17 Claims
-
1. A compound of the formula:
-
B-L-D or a salt thereof, wherein B is a prostate specific membrane antigen (PSMA) binding ligand; L comprises at least one polyoxyalkylene portion and at least one Glu, Asp, Cys, beta-amino Ala, Gly, beta Ala, amino valeric acid, or amino caproic acid, wherein the linker is at least 14 atoms in length and has at least one side chain group comprising a hydrophobic alkyl, cycloalkyl, aryl or arylalkyl; and D is a radioactive isotope of a metal coordinated to a chelating group. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
Specification